{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"Should any 2 patients within the first 3 to 6 patients experience treatment limiting toxicity requiring cessation of treatment prior to the conclusion of the first cycle, the maximum tolerated dose will have been exceeded and patients will be enrolled to the next lower dose.","groups":[{"description":"Drug: Pentostatin Regimen A: Cycle 1: 4 mg/m\\^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m\\^2 on day 1 of 21 day cycle\n\nOther Names:\n\n• Nipent Drug: Cyclophosphamide Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle\n\nOther Names:\n\n• Cytoxan\n\nDrug: SS1(dsFv)PE38 Regimen A: Cycle 1: 35 mcg/kg or 25 mcg/kg days 10, 12 and 14. Cycles 2-4: Days 2, 4, and 6, for a maximum of six treatment cycles.\n\nDuring Phase 2 SS1P was administered from 2 different Lots at 35mcg/kg (Lot F1L129J01 and Lot07310809). It was discovered that Lot F1L129J01 was more potent than Lot 07310809, therefore, a dose de-escalation was done for 8 participants who received that Lot to determine the MTD specific to the Lot.","id":"OG000","title":"Meso., Peritoneal, Pleural & Pancreatic Regimen A"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Days 1, 3, and 5 of a 21 day cycle","title":"Recommended Phase 2 Dose (RP2D) in Drug Lot FIL129J01","type":"PRIMARY","unitOfMeasure":"mcg/kg/dose"}